HSP90 inhibitor

DRUG CLASS:

HSP90 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	pimitespib Sensitive: B - Late Trials pimitespib Sensitive : B	pimitespib Sensitive: B - Late Trials pimitespib Sensitive : B
BRAF V600K	Solid Tumor	BRAF V600K	Solid Tumor	trametinib + dabrafenib + AT13387 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + AT13387 Sensitive : C2	trametinib + dabrafenib + AT13387 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + AT13387 Sensitive : C2
BRAF V600E	Solid Tumor	BRAF V600E	Solid Tumor	trametinib + dabrafenib + AT13387 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + AT13387 Sensitive : C2	trametinib + dabrafenib + AT13387 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + AT13387 Sensitive : C2
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2
TP53 mutation	Ovarian Cancer	TP53 mutation	Ovarian Cancer	ADX-1612 Sensitive: C2 – Inclusion Criteria ADX-1612 Sensitive : C2	ADX-1612 Sensitive: C2 – Inclusion Criteria ADX-1612 Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	IPI-504 Sensitive: C3 – Early Trials IPI-504 Sensitive : C3	IPI-504 Sensitive: C3 – Early Trials IPI-504 Sensitive : C3
BRAF V600E	Melanoma	BRAF V600E	Melanoma	vemurafenib + XL888 Sensitive: C3 – Early Trials vemurafenib + XL888 Sensitive : C3	vemurafenib + XL888 Sensitive: C3 – Early Trials vemurafenib + XL888 Sensitive : C3
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab + pimitespib Sensitive: C3 – Early Trials nivolumab + pimitespib Sensitive : C3	nivolumab + pimitespib Sensitive: C3 – Early Trials nivolumab + pimitespib Sensitive : C3
TMB-H + PD-L1 expression	Colorectal Cancer	TMB-H + PD-L1 expression	Colorectal Cancer	nivolumab + pimitespib Sensitive: C3 – Early Trials nivolumab + pimitespib Sensitive : C3	nivolumab + pimitespib Sensitive: C3 – Early Trials nivolumab + pimitespib Sensitive : C3
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	olaparib + AT13387 Sensitive: C3 – Early Trials olaparib + AT13387 Sensitive : C3	olaparib + AT13387 Sensitive: C3 – Early Trials olaparib + AT13387 Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib + AT13387 Sensitive: C3 – Early Trials olaparib + AT13387 Sensitive : C3	olaparib + AT13387 Sensitive: C3 – Early Trials olaparib + AT13387 Sensitive : C3
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	AUY922 Sensitive: C3 – Early Trials AUY922 Sensitive : C3	AUY922 Sensitive: C3 – Early Trials AUY922 Sensitive : C3
PDGFRA D842V	Gastrointestinal Stromal Tumor	PDGFRA D842V	Gastrointestinal Stromal Tumor	pimitespib Sensitive: C4 – Case Studies pimitespib Sensitive : C4	pimitespib Sensitive: C4 – Case Studies pimitespib Sensitive : C4
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	IPI-504 Sensitive: D – Preclinical IPI-504 Sensitive : D	IPI-504 Sensitive: D – Preclinical IPI-504 Sensitive : D
BCR-FGFR1 fusion	Leukemia	BCR-FGFR1 fusion	Leukemia	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D
BCR-FGFR1 fusion	Leukemia	BCR-FGFR1 fusion	Leukemia	infigratinib + ADX-1612 Sensitive: D – Preclinical infigratinib + ADX-1612 Sensitive : D	infigratinib + ADX-1612 Sensitive: D – Preclinical infigratinib + ADX-1612 Sensitive : D
KRAS G12D + TP53 deletion	Lung Adenocarcinoma	KRAS G12D + TP53 deletion	Lung Adenocarcinoma	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D
EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D
NRAS mutation	Melanoma	NRAS mutation	Melanoma	XL888 Sensitive: D – Preclinical XL888 Sensitive : D	XL888 Sensitive: D – Preclinical XL888 Sensitive : D
TP53 deletion	Colorectal Cancer	TP53 deletion	Colorectal Cancer	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D
TP53 deletion	Non Small Cell Lung Cancer	TP53 deletion	Non Small Cell Lung Cancer	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D
FLT3 D835	Acute Myelogenous Leukemia	FLT3 D835	Acute Myelogenous Leukemia	LAM 003 Sensitive: D – Preclinical LAM 003 Sensitive : D	LAM 003 Sensitive: D – Preclinical LAM 003 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	LAM 003 Sensitive: D – Preclinical LAM 003 Sensitive : D	LAM 003 Sensitive: D – Preclinical LAM 003 Sensitive : D
KIT exon 11 mutation + KIT exon 17 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation + KIT exon 17 mutation	Gastrointestinal Stromal Tumor	sunitinib + IPI 493 Sensitive: D – Preclinical sunitinib + IPI 493 Sensitive : D	sunitinib + IPI 493 Sensitive: D – Preclinical sunitinib + IPI 493 Sensitive : D
KIT exon 9 mutation	Gastrointestinal Stromal Tumor	KIT exon 9 mutation	Gastrointestinal Stromal Tumor	IPI 493 Sensitive: D – Preclinical IPI 493 Sensitive : D	IPI 493 Sensitive: D – Preclinical IPI 493 Sensitive : D
NPM1-ALK I1171T	Non-Hodgkin’s Lymphoma	NPM1-ALK I1171T	Non-Hodgkin’s Lymphoma	AUY922 Sensitive: D – Preclinical AUY922 Sensitive : D	AUY922 Sensitive: D – Preclinical AUY922 Sensitive : D
NPM1-ALK F1174C	Non-Hodgkin’s Lymphoma	NPM1-ALK F1174C	Non-Hodgkin’s Lymphoma	AUY922 Sensitive: D – Preclinical AUY922 Sensitive : D	AUY922 Sensitive: D – Preclinical AUY922 Sensitive : D

HSP90 inhibitor

HSP90 inhibitor

Associations(44)

Associations
(44)